

Resource Summary Report

Generated by [NIF](#) on Aug 12, 2026

Hep-G2/2.2.15

RRID:CVCL_L855

Type: Cell Line

Proper Citation

RRID:CVCL_L855

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_L855

Proper Citation: RRID:CVCL_L855

Description: Cell line Hep-G2/2.2.15 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Hepatoblastoma

Defining Citation: [PMID:3029758](#), [PMID:8224613](#), [PMID:21448419](#), [PMID:29481805](#)

Comments: Virology: Contains 2 head to tails stably integrated hepatitis B virus (HBV) of the D-genotype., Population: Caucasian.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Hep-G2/2.2.15

Synonyms: HEP-G2/2.2.15, Hep-G2/2215, HepG2/2215, HepG2-2.2.15, HepG2 2.2.15, HepG2.2.15, HepG2(2.2.15), 2.2.15

Cross References: BTO:BTO_0005621, CLO:CLO_0001176, CLDB:cl33, cancercellines:CVCL_L855, CCTCC:GDC0141, ChEMBL-Cells:ChEMBL3833241, ChEMBL-Targets:ChEMBL4296438, CLS:305227, Cosmic:979733, Millipore:SCC249, PubChem_Cell_line:CVCL_L855, Wikidata:Q54882787

ID: CVCL_L855

Hierarchy: cvcl_0027

Record Creation Time: 20220427T220334+0000

Record Last Update: 20260809T000802+0000

Ratings and Alerts

No rating or validation information has been found for Hep-G2/2.2.15.

No alerts have been found for Hep-G2/2.2.15.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 543 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Hou H, et al. (2026) Design, Synthesis, and Biological Evaluation of Novel Tetrandrine Derivatives Targeting AKT1 for Hepatocellular Carcinoma Therapy: Integration of Network Pharmacology, Molecular Dynamics Simulation, and Experimental Validation. ACS omega, 11(21), 30812.

Chen Q, et al. (2026) Single- and dual-target CAR-T cells targeting HBsAg and GPC3 to balance safety and antitumor efficacy in HBV-positive hepatocellular carcinoma. iScience, 29(8), 116844.

Yang Y, et al. (2026) Quercetin potentially suppresses HBV activity through targeting the RIG-I/MAVS pathway. iScience, 29(5), 115704.

Zhang R, et al. (2026) TRMT6-Mediated m1A Modification of CDK9 mRNA is a Dual-Pronged Pathogenic Driver for HBV-Related Hepatocellular Carcinoma. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(39), e14172.

Dong Z, et al. (2025) The LUBAC subunit HOIL-1 promotes the progression of HBV-associated hepatocellular carcinoma independently of linear ubiquitination. Experimental & molecular medicine, 57(10), 2317.

Liu Y, et al. (2025) Hepatitis B virus core/capsid protein induces hepatocellular carcinoma progression via long non-coding RNA KCNQ1OT1/miR-335-5p/CDC7 axis. Translational cancer research, 14(6), 3319.

Yang Y, et al. (2025) HBV-encoded circRNA-5 promotes hepatocellular carcinoma progression by regulating the miR-9-3p/Hippo signaling axis. Microbiology spectrum, e0143925.

Deng R, et al. (2024) ISG12a promotes immunotherapy of HBV-associated hepatocellular carcinoma through blocking TRIM21/AKT/?-catenin/PD-L1 axis. iScience, 27(4), 109533.

Smiriglia A, et al. (2023) Sex difference in liver diseases: How preclinical models help to dissect the sex-related mechanisms sustaining NAFLD and hepatocellular carcinoma. *iScience*, 26(12), 108363.

Wang Y, et al. (2023) HBx-Induced HSPA8 Stimulates HBV Replication and Suppresses Ferroptosis to Support Liver Cancer Progression. *Cancer research*, 83(7), 1048.

Zhang B, et al. (2023) An HBV susceptibility variant of KNG1 modulates the therapeutic effects of interferons α and β 1 in HBV infection by promoting MAVS lysosomal degradation. *EBioMedicine*, 94, 104694.

Lam MSY, et al. (2023) G9a/GLP inhibition during ex vivo lymphocyte expansion increases in vivo cytotoxicity of engineered T cells against hepatocellular carcinoma. *Nature communications*, 14(1), 563.

Shi Y, et al. (2023) Release of hepatitis B virions is positively regulated by glucose-regulated protein 78 through direct interaction with preS1. *Journal of medical virology*, 95(1), e28271.

Ye Z, et al. (2023) Synthesis and biological evaluation of esculetin derivatives as potential anti-HBV agents. *Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents*, 32(5), 899.

Liu Y, et al. (2023) Apolipoprotein H induces sex-specific steatohepatitis and gut dysbiosis during chronic hepatitis B infection. *iScience*, 26(3), 106100.

Qin YF, et al. (2023) Hepatitis B Virus Surface Antigen Promotes Stemness of Hepatocellular Carcinoma through Regulating MicroRNA-203a. *Journal of clinical and translational hepatology*, 11(1), 118.

Doan PTB, et al. (2023) Super-Resolution Microscopy Analysis of Hepatitis B Viral cccDNA and Host Factors. *Viruses*, 15(5).

Lee YC, et al. (2023) Development of anti-aflatoxin B1 nanobodies from a novel mutagenesis-derived synthetic library for traditional Chinese medicine and foods safety testing. *Journal of biological engineering*, 17(1), 30.

Han Y, et al. (2023) BMP9-induced vascular normalisation improves the efficacy of immunotherapy against hepatitis B virus-associated hepatocellular carcinoma. *Clinical and translational medicine*, 13(5), e1247.

Kwon H, et al. (2023) Peptidyl-prolyl cis/trans isomerase Pin1 interacts with hepatitis B virus core particle, but not with HBc protein, to promote HBV replication. *Frontiers in cellular and infection microbiology*, 13, 1195063.